The majority of the body's Basement Membranes (BMs), including vascular basement membranes, contain the protein endostatin. Recombinant human endostatin has been shown to significantly improve patients' chances of survival when used to treat late-stage non-small cell lung cancer in a few clinical studies (NSCLC).
The Recombinant Human Endostatin Market is booming as a result of government initiatives to lower the cost of anticancer medications. The market expansion is anticipated to be hampered by growing difficulties in the significant production of recombinant human endostatin. Moreover, increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market.
Read More @ https://cmiinfonest.blogspot.com/2022/12/recombinant-human-endostatin-market.html
